Jump to content

Semaglutide

From Wikipedia
semaglutide
type of chemical entity
Subclass ofsynthetic peptide, glucagon-like peptide-1 Edit
Chemical formulaC₁₈₇H₂₉₁N₄₅O₅₉ Edit
Canonical SMILESCCC(C)C(NC(=O)C(Cc1ccccc1)NC(=O)C(CCC(=O)O)NC(=O)C(CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CCC(NC(=O)CCCCCCCCCCCCCCCCC(=O)O)C(=O)O)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(N)=O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(NC(=O)C(Cc1ccccc1)NC(=O)C(NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(C)(C)NC(=O)C(N)Cc1cnc[nH]1)C(C)O)C(C)O)C(C)C)C(=O)NC(C)C(=O)NC(Cc1c[nH]c2ccccc12)C(=O)NC(CC(C)C)C(=O)NC(C(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)O)C(C)C Edit
Isomeric SMILESCC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)O)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CC[C@H](C(=O)O)NC(=O)CCCCCCCCCCCCCCCCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)N)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC5=CC=CC=C5)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)C(C)(C)NC(=O)[C@H](CC6=CN=CN6)N Edit
Active ingredient inOzempic Edit
Medical condition treatedtype 2 diabetes, obesity Edit
Legal status (medicine)boxed warning Edit
Described at URLhttps://bnf.nice.org.uk/drugs/semaglutide/ Edit

Semaglutide be antidiabetic medication dem use for de treatment of type 2 diabetes den anti-obesity medication dem use for long-term weight management.[1][2][3] Ebe peptide similar to de hormone glucagon-like peptide-1 (GLP-1), dem modify plus side chain.[4][5] Dem fi administer am by subcutaneous injection anaa dem fi take am orally.[6][7][8][9] Dem dey sell am under de brand names Ozempic[7] den Rybelsus[8] for diabetes, den under de brand name Wegovy for weight loss.[9]

Semaglutide be glucagon-like peptide-1 receptor agonist.[7][8][9] De most common side effects dey include nausea, vomiting, diarrhea, abdominal pain, den constipation.[7][10][11][12][13]

Na dem approve am for medical use insyd de US insyd 2017.[7][14] Insyd 2022, na ebe de 48th most commonly prescribed medication insyd de United States, plus more dan 13 million prescriptions.[15][16]

References

[edit | edit source]
  1. ↑ Singh G, Krauthamer M, Bjalme-Evans M (January 2022). "Wegovy (semaglutide): a new weight loss drug for chronic weight management". Journal of Investigative Medicine. 70 (1): 5–13. doi:10.1136/jim-2021-001952. PMC 8717485. PMID 34706925.
  2. ↑ Phillips A, Clements JN (February 2022). "Clinical review of subcutaneous semaglutide for obesity". Journal of Clinical Pharmacy and Therapeutics. 47 (2): 184–193. doi:10.1111/jcpt.13574. PMID 34964141. S2CID 245538758.
  3. ↑ Amaro A, Sugimoto D, Wharton S (January 2022). "Efficacy and safety of semaglutide for weight management: evidence from the STEP program". Postgraduate Medicine. 134 (sup1): 5–17. doi:10.1080/00325481.2022.2147326. PMID 36691309. S2CID 256192982.
  4. ↑ Doggrell SA (March 2018). "Semaglutide in type 2 diabetes - is it the best glucagon-like peptide 1 receptor agonist (GLP-1R agonist)?" (PDF). Expert Opinion on Drug Metabolism & Toxicology. 14 (3): 371–377. doi:10.1080/17425255.2018.1441286. PMID 29439603. S2CID 3421553. Archived (PDF) from the original on 5 May 2020. Retrieved 12 December 2019.
  5. ↑ Goldenberg RM, Steen O (March 2019). "Semaglutide: Review and Place in Therapy for Adults With Type 2 Diabetes". Canadian Journal of Diabetes. 43 (2): 136–145. doi:10.1016/j.jcjd.2018.05.008. PMID 30195966.
  6. ↑ Hughes S, Neumiller JJ (January 2020). "Oral Semaglutide". Clinical Diabetes. 38 (1): 109–111. doi:10.2337/cd19-0079. PMC 6969659. PMID 31975761.
  7. ↑ 7.0 7.1 7.2 7.3 7.4 "Ozempic- semaglutide injection, solution". DailyMed. Archived from the original on 5 June 2021. Retrieved 5 June 2021.
  8. ↑ 8.0 8.1 8.2 "Rybelsus- oral semaglutide tablet". DailyMed. Archived from the original on 5 June 2021. Retrieved 5 June 2021.
  9. ↑ 9.0 9.1 9.2 "Wegovy- semaglutide injection, solution". DailyMed. 4 June 2021. Archived from the original on 14 December 2021. Retrieved 11 March 2022.
  10. ↑ "Ozempic EPAR". European Medicines Agency (EMA). 8 February 2018. Archived from the original on 25 October 2020. Retrieved 26 September 2020.
  11. ↑ "Rybelsus EPAR". European Medicines Agency (EMA). 29 January 2020. Archived from the original on 14 August 2020. Retrieved 26 September 2020.
  12. ↑ "Wegovy EPAR". European Medicines Agency. 6 January 2022. Archived from the original on 2 July 2022. Retrieved 11 March 2022.
  13. ↑ "Ozempic Drug Trial Snapshot". U.S. Food and Drug Administration (FDA). 5 December 2017. Archived from the original on 31 December 2023. Retrieved 31 December 2023. This article incorporates text from this source, which is in the public domain.
  14. ↑ "Drug Approval Package: Ozempic (semaglutide) Injection". U.S. Food and Drug Administration (FDA). 16 January 2018. Archived from the original on 1 March 2021. Retrieved 26 September 2020.
  15. ↑ "The Top 300 of 2022". ClinCalc. Archived from the original on 30 August 2024. Retrieved 30 August 2024.
  16. ↑ "Semaglutide Drug Usage Statistics, United States, 2013 - 2022". ClinCalc. Retrieved 30 August 2024.
[edit | edit source]

Semaglutide at Wikipedia ein sisto projects

Scholia get profile for semaglutide (Q27261089).

  • "Semaglutide tablet". MedlinePlus.
  • Clinical trial number NCT03574597 for "Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity (SELECT)" at ClinicalTrials.gov
Dem retrieve am from "https://gpe.wikipedia.org/w/index.php?title=Semaglutide&oldid=40352"